Please login to the form below

Not currently logged in
Email:
Password:

tildrakizumab

This page shows the latest tildrakizumab news and features for those working in and with pharma, biotech and healthcare.

BMS psoriasis drug hits the mark in phase II

BMS psoriasis drug hits the mark in phase II

including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Almirall paid $50m upfront to Sun Pharma for a licence to tildrakizumab (an IL-23p19 antibody) in Europe, and the deal includes payments of undisclosed development and regulatory milestones as well ... Acquisition. 78. Sun Pharma/ Almirall. Tildrakizumab

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics